- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06310837
Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis
March 13, 2024 updated by: Zhongshan Ophthalmic Center, Sun Yat-sen University
Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis: A Multicenter, Randomized, Non-inferiority Clinical Trial
This is a multi-center, prospective, randomized controlled non-inferior clinical study.
A total of 120 subjects with non-infectious intermediate, posterior, or panuveitis were enrolled in Zhongshan Ophthalmic Center and three other centers.
They were randomly assigned to the experimental group and the control group according to ( 1 : 1 ).
We hypothesized that adalimumab biosimilars combined with immunosuppressive agents in the treatment of non-infectious uveitis is not inferior to glucocorticoids combined with immunosuppressive agents, and there are no additional adverse events and safety issues.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The study will be followed up in the screening-baseline period and at 4,8,12,18,24,36, and 48 weeks after the start of the study drug.
The ETDRS letter number change of the best corrected visual acuity ( BCVA ) at 24 weeks compared with the baseline was used as the main indicator.
The last follow-up was performed at 48 weeks.
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wei Chi
- Phone Number: 13710616456
- Email: chiwei@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Zhongshan Ophthalmic Center
-
Contact:
- Wei Chi
- Phone Number: 13710616456
- Email: chiwei@mail.sysu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 to 70 years old ( including boundary value ), male or female.
- At least one eye is diagnosed as noninfectious intermediate uveitis, posterior uveitis or panuveitis.
- Subject is on prednisone ≥ 10 mg/day (or corticosteroid equivalent) for at least 2 weeks prior to Screening and remains on the same dose from screening to baseline visit.
- At least one eye is diagnosed as active uveitis at baseline;
- Subject is voluntary to participate in the study and sign the informed consent form.
Exclusion Criteria:
- Subject with isolated anterior uveitis.
- Subject with prior inadequate response to or intolerance to high-dose corticosteroids (equivalent of prednisone 1 mg/kg/day or 60 to 80 mg/day).
- Subject is suspected or diagnosed as infectious uveitis.
- Uncontrolled glaucoma or high intraocular pressure, defined as intraocular pressure>25 mmHg after treatment with ≥ 2 anti-glaucoma drugs or evidence of glaucomatous optic nerve injury.
- Subject with best corrected visual acuity (BCVA) worse than 20/400 (ETDRS logMAR > 1.34) in the better eye.
- Subject with other fundus diseases.
- Subject with demyelinating diseases.
- Subject has a contraindication to pupil dilation with mydriatic eyedrops.
- Subject with corneal or lens opacity that precludes visualization of the anterior segment and fundus.
- Topical corticosteroids and/or topical NSAID>3 drops per day in the 14 days prior to baseline; Dexamethasone/betamethasone or equivalent subconjunctival steroid within 30 days prior to baseline; Parafbulbar, intravitreal (IVT), suprasoroidal, or periocular corticosteroid injections were administered within 60 days prior to baseline; Received IVT anti-VEGF therapies less than 60 days prior to baseline; Dexamethasone (Ozurdex) IVT implant within 6 months prior to baseline; Fluocinolone acetonide IVT implant within 3 years prior to baseline.
- Subject with history of prior intraocular surgery within 90 days prior to baseline or any planned (elective) eye surgery within the next 1 year from baseline.
- Subject is diagnosised or suspected tuberculosis, hepatitis B virus, hepatitis C virus, HIV, syphilis infection or with other uncontrolled active infections or other infections that would put the subject at uncontrolled risk.
- Subject with severe, progressive, or uncontrolled symptoms of renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiovascular, neurological, or cerebral diseases or with malignant tumors or with moderate to severe heart failure and subjects who are considered by the investigator to be at unacceptable risk by participating in the study.
- Prior biologic and immunosuppressant therapy other than corticosteroids at any time.
- Subject with a systemic inflammatory disease that requires continued therapy with oral corticosteroids or a prohibited immunosuppressive agent at Screening or Baseline visits.
- Fertile woman who has a positive serum pregnancy test at the screening visit or plans for pregnancy and sperm donation during the trial and within 6 months after the end of the study.
- Other subjects who are considered by the investigator to be inappropriated for enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ADA+MMF group
Adalimumab biosimilars with immunosuppressants therapy
|
Adalimumab biosimilars: 80 mg was subcutaneously injected for the first time in the first week, and then 40 mg was subcutaneously injected every two weeks from the first week to the 48 th week.
Other Names:
Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid
Other Names:
|
Active Comparator: Corticosteroids+MMF group
Corticosteroids with immunosuppressive therapy;
|
Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid
Other Names:
Patients received no less than 1 mg / kg.d glucocorticoid at week 0, then implemented according to the standard reduction scheme.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of ETDRS letter count for BCVA at week 24 from baseline
Time Frame: week 24
|
The best corrected visual acuity of the patient would be examined by the ETDRS visual acuity chart according to the visual acuity examination SOP.
Change of ETDRS letter count for BCVA at week 24 from baseline were the main indicator, the outcome at other follow-up time points(Baseline, weeks 4, 8, 12, 18, 36, 48)would also be included in the outcome analysis.
|
week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with weight gain at week 24 from baseline
Time Frame: week 24
|
Patients would be instructed to remove shoes and heavy clothing for measurement, and weight gain is defined as a 5% increase from baseline.
|
week 24
|
Time of treatment failures
Time Frame: week 24
|
Treatment failure is defined as an increase in the degree of inflammation in one or more of four areas, including choroidal and/or retinal vasculopathy, macular edema, anterior chamber cell grade, and vitreous opacity grade, assessed by the investigators from week 4 to the end of follow-up.
|
week 24
|
Number of treatment failures
Time Frame: week 24
|
Treatment failure is defined as an increase in the degree of inflammation in one or more of four areas, including choroidal and/or retinal vasculopathy, macular edema, anterior chamber cell grade, and vitreous opacity grade, assessed by the investigators from week 4 to the end of follow-up.
|
week 24
|
Change of Visual Functioning Questionnaire- 25 (VFQ-25) composite score from baseline
Time Frame: week 24
|
The changes of each follow-up time point from the baseline are evaluated according to VFQ-25 visual function evaluation scale.To calculate an overall composite score for the VFQ-25, we will simply average the vision-targeted subscale scores, excluding the general health rating question.(100=best,
0=worst possible score)
|
week 24
|
Change of anterior chamber inflammation at week 24 from baseline
Time Frame: week 24
|
Change of anterior chamber inflammation assessed by research doctors with slit-lamp according to the International Uveitis Organization ( SUN group ) classification criteria.
|
week 24
|
Change of vitreous opacity at week 24 from baseline
Time Frame: week 24
|
Change of vitreous opacity assessed by research doctors with slit-lamp according to the International Uveitis Organization ( SUN group ) classification criteria.
|
week 24
|
Change of the retinal and choroidal inflammation at week 24 from baseline
Time Frame: week 24
|
Change of the retinal and choroidal inflammation assessed by fluorescein angiography.
|
week 24
|
Change of the thickness of retina and choroid in macular area at week 24 from baseline
Time Frame: week 24
|
Change of the thickness of retina and choroid in macular area evaluated by Optical Coherence Tomography (OCT) or Optical Coherence Tomography Angiography (OCTA).
|
week 24
|
Occurrence of skin abnormalities at the end of study
Time Frame: week 48
|
The occurrence of skin abnormalities reported by research doctors based on adverse reaction evaluation criteria (CTCAE v5.0).
|
week 48
|
Occurrence of hypertension at the end of study
Time Frame: week 48
|
The occurrence of hypertension assessed by electronic blood manometer based on adverse reaction evaluation criteria (CTCAE v5.0).
|
week 48
|
Occurrence of hyperglycemia at the end of study
Time Frame: week 48
|
The occurrence of hyperglycemia assessed by venous blood glucose testing based on adverse reaction evaluation criteria (CTCAE v5.0).
|
week 48
|
Occurrence of active tuberculosis infection at the end of study
Time Frame: week 48
|
The occurrence of active tuberculosis infection assessed by pulmonary X-ray examination and tuberculosis bacterial T cell detection and evaluated by research doctors.
|
week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Wei Chi, Zhongshan Ophthalmic Center, Sun Yat-sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 27, 2024
Primary Completion (Estimated)
August 27, 2024
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
February 20, 2024
First Submitted That Met QC Criteria
March 13, 2024
First Posted (Actual)
March 15, 2024
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 13, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023KYPJ300
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uveitis
-
Priovant Therapeutics, Inc.Active, not recruitingNon-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious Pan UveitisUnited States
-
Stanford UniversitySanten Inc.WithdrawnPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
University of NebraskaUnknownPosterior Uveitis | Intermediate Uveitis | Pan-uveitisUnited States
-
Novartis PharmaceuticalsCompletedNon-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious PanuveitisUnited States, United Kingdom
-
EyePoint Pharmaceuticals, Inc.CompletedPanuveitis | Posterior Uveitis | Intermediate UveitisIndia
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
The New York Eye & Ear InfirmaryUnknownPanuveitis | Uveitis | Posterior Uveitis | Anterior UveitisUnited States
-
CHU de Quebec-Universite LavalCompletedIntermediate Uveitis | Anterior UveitisCanada
-
University of California, San FranciscoKhon Kaen University; King Chulalongkorn Memorial Hospital; Huang Pacific FoundationRecruitingCytomegalovirus Anterior UveitisThailand, United States
-
Duke UniversityCompletedPosterior Uveitis | Intermediate UveitisUnited States
Clinical Trials on Adalimumab Biosimilars Injection
-
Hanyang University Seoul HospitalLinical KoreaNot yet recruitingAnkylosing Spondylitis | Axial Spondyloarthritis
-
Lundquist Institute for Biomedical Innovation at...Active, not recruitingMucopolysaccharidosis I | Mucopolysaccharidosis II | Mucopolysaccharidosis VIUnited States
-
St Vincent's Hospital MelbourneAbbVie; Australasian Gastro Intestinal Research FoundationUnknownInflammatory Bowel Diseases | Crohn Disease | Stricture; BowelAustralia
-
University of PennsylvaniaCompletedCardiovascular Disease | PsoriasisUnited States
-
GlaxoSmithKlineCompleted
-
University of OxfordNational Institute for Health Research, United Kingdom; 180 Life SciencesCompletedFrozen ShoulderUnited Kingdom
-
Centre Hospitalier Universitaire de Saint EtienneDirection Générale de l'Offre de SoinsNot yet recruitingUveitis | Chronic DiseaseFrance
-
ANRS, Emerging Infectious DiseasesRecruitingTnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis (TIMPANI)Tuberculous Meningitis | HIV I InfectionMozambique, Brazil, Zambia
-
Erasmus Medical CenterProthya BiosolutionsUnknownHidradenitis SuppurativaNetherlands
-
University Hospital, GenevaCompleted